Carisma Therapeutics INC Form 4 insider transactions

Carisma Therapeutics' Chief Scientific Officer, Michael Klichinsky, exercised stock options and subsequently sold 56,982 shares of common stock.

Carisma Therapeutics' Chief Scientific Officer, Michael Klichinsky, sold all of his direct common stock holdings over three days in early October 2025, pursuant to a Rule 10b5-1 plan.

Carisma Therapeutics Inc. is progressing its merger with OrthoCellix, securing a $5.0 million investment from Ocugen and extending its Nasdaq compliance deadline.

Carisma Therapeutics Inc. stockholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-50, granting the Board discretion on implementation.

Carisma Therapeutics Inc. received an additional delisting notice from Nasdaq for failing to meet the minimum bid price requirement and plans a reverse stock split to regain compliance while also pursuing a merger with OrthoCellix, Inc.

Carisma Therapeutics Inc. and OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., have entered into a definitive merger agreement, with OrthoCellix becoming a wholly-owned subsidiary of Carisma, alongside a proposed concurrent financing.

Carisma Therapeutics Inc. has announced a definitive agreement to merge with OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., in a strategic move that includes a concurrent financing.

Carisma Therapeutics Inc. and OrthoCellix, a wholly-owned subsidiary of Ocugen, Inc., have announced a proposed merger, with OrthoCellix becoming a wholly-owned subsidiary of Carisma, contingent on various conditions and a concurrent financing.

Carisma Therapeutics Inc. has entered into a definitive merger agreement with OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., in an all-stock transaction that will pivot the combined company's focus to regenerative cell therapies for orthopedic diseases.

Michael Klichinsky, Chief Scientific Officer of Carisma Therapeutics Inc., reports the acquisition of stock options.

Steven Kelly, President and CEO of Carisma Therapeutics Inc., reports the acquisition of 500,000 stock options on January 28, 2025.

Director Sohanya Roshan Cheng acquired stock options for 38,700 shares of Carisma Therapeutics Inc. on October 31, 2024.

Marella Thorell, a director of Carisma Therapeutics Inc., acquired stock options on July 1, 2024.

David Scadden, a director of Carisma Therapeutics Inc., acquired stock options for 38,700 shares on July 1, 2024.

Director Sanford Zweifach acquired stock options for 19,350 shares of Carisma Therapeutics Inc. on June 26, 2024.

Director Briggs Morrison acquired 19,350 stock options in Carisma Therapeutics Inc. on June 26, 2024.

Director John Hohneker reports acquisition of stock options in Carisma Therapeutics Inc.

Director Michael Torok acquired 19,350 stock options in Carisma Therapeutics Inc. on June 26, 2024.

Richard Steven Morris, CFO of Carisma Therapeutics Inc., reports the acquisition of stock options.

Michael Klichinsky, Chief Scientific Officer of Carisma Therapeutics Inc., reports the acquisition of 85,000 stock options.

Carisma Therapeutics' CEO, Steven Kelly, was granted stock options to purchase 125,000 shares of common stock on June 17, 2024.

Director John Hohneker reports the acquisition of stock options in Carisma Therapeutics Inc.